- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 84-98 of
153 results
1007 Exhibit: Ex 1007 Grimsgaard et al, Highly Purified Eicosapentaenoic Acid and...
Document
IPR2022-00215, No. 1007-6 Exhibit - Ex 1007 Grimsgaard et al, Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid in Humans Have Similar Triacylglycerol Lowering Effects but D...
|
|
Cite Document
1025 Exhibit: Ex 1025 Amarin Response to US Patent Office re US Patent Applicati...
Document
IPR2022-00215, No. 1025-30 Exhibit - Ex 1025 Amarin Response to US Patent Office re US Patent Application No 17768,906 Aug 26, 2013 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1041 Exhibit: Ex 1041 US Patent No 6,479,544 to Horrobin
Document
IPR2022-00215, No. 1041-46 Exhibit - Ex 1041 US Patent No 6,479,544 to Horrobin (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1027 Exhibit: Ex 1027 Saito et al, Effects of EPA on Coronary Artery Disease in Hyp...
Document
IPR2022-00215, No. 1027-32 Exhibit - Ex 1027 Saito et al, Effects of EPA on Coronary Artery Disease in Hypercholesterolemic Patients with Multiple Risk Factors Sub Analysis of Primary Preve...
|
|
Cite Document
1035 Exhibit: Ex 1035 Declaration of C Rosebraugh from Amarin Pharma, Inc et al v...
Document
IPR2022-00215, No. 1035-40 Exhibit - Ex 1035 Declaration of C Rosebraugh from Amarin Pharma, Inc et al v US FDA et al, No 15 3588 SDNY (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1016 Exhibit: Ex 1016 Shinozaki et al, The Long Term Effect of Eicosapentaenoic A...
Document
IPR2022-00215, No. 1016-17 Exhibit - Ex 1016 Shinozaki et al, The Long Term Effect of Eicosapentaenoic Acid on Serum Levels of Lipoprotein a and Lipids in Patients with Vascular Disease, 2...
|
|
Cite Document
1049 Exhibit: Ex 1049 Crestor rosuvastatin calcium Label 112007
Document
IPR2022-00215, No. 1049-54 Exhibit - Ex 1049 Crestor rosuvastatin calcium Label 112007 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 1
Document
IPR2022-00215, No. 1013-56 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 1 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 4
Document
IPR2022-00215, No. 1013-59 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 4 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1033 Exhibit: Ex 1033 Vascepa Label 122019
Document
IPR2022-00215, No. 1033-38 Exhibit - Ex 1033 Vascepa Label 122019 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1032 Exhibit: Ex 1032 Notice of Allowability from US Patent Office re US Patent App...
Document
IPR2022-00215, No. 1032-37 Exhibit - Ex 1032 Notice of Allowability from US Patent Office re US Patent Application No 13614,111 Feb 11, 2013 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 13
Document
IPR2022-00215, No. 1013-68 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 13 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1019 Exhibit: Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hik...
Document
IPR2022-00215, No. 1019-3 Exhibit - Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hikma Pharms USA Inc, No 16 2525 D Nev Part 3 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1019 Exhibit: Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hik...
Document
IPR2022-00215, No. 1019-2 Exhibit - Ex 1019 Plaintiffs Validity Contentions from Amarin Pharma, Inc v Hikma Pharms USA Inc, No 16 2525 D Nev Part 2 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
1013 Exhibit: Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 3
Document
IPR2022-00215, No. 1013-3 Exhibit - Ex 1013 Expert Declaration of Sylvia Hall Ellis, PhD Part 3 (P.T.A.B. Nov. 30, 2021)
|
|
Cite Document
